<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic criteria: accelerated phase of chronic myelogenous leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic criteria: accelerated phase of chronic myelogenous leukemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Diagnostic criteria: accelerated phase of chronic myelogenous leukemia</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">MD Anderson*</td> <td class="subtitle1">Sokal et al<sup>¶</sup></td> <td class="subtitle1">WHO<sup>Δ</sup></td> </tr> <tr> <td> <p>PB blasts ≥15%</p> PB blasts + pro ≥30%</td> <td>PB or BM blasts ≥5%</td> <td>PB or BM blasts 10 to 19%</td> </tr> <tr> <td>PB baso ≥20%</td> <td>PB basophils ≥20%</td> <td>PB basophils ≥20%</td> </tr> <tr> <td>Platelets &lt;100,000/microL not related to therapy</td> <td>Thrombocytopenia, not related to therapy</td> <td>Platelets &lt;100,000/microL, unrelated to therapy</td> </tr> <tr> <td rowspan="8">Cytogenetic evolution</td> <td>Cytogenetic evolution</td> <td>Cytogenetic evolution or additional clonal chromosomal abnormalities in Ph+ cells at diagnosis that include "major route" abnormalities, complex karyotype, or abnormalities of 3q26.2</td> </tr> <tr> <td>Platelets &gt;1 million/microL despite adequate therapy</td> <td>Platelets &gt;1,000,000/microL unresponsive to therapy</td> </tr> <tr> <td>Marrow collagen fibrosis</td> <td> </td> </tr> <tr> <td>Anemia, unrelated to Rx</td> <td> </td> </tr> <tr> <td>Progressive splenomegaly</td> <td>Progressive splenomegaly and increasing WBC unresponsive to therapy</td> </tr> <tr> <td>WBC doubling time &lt;5 days</td> <td> </td> </tr> <tr> <td>Unexplained fever</td> <td> </td> </tr> <tr> <td>Pelger-Huett-like neutrophils, nucleated RBCs, megakaryocyte fragments</td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Examples of "major route" abnormalities defined by the WHO include second Ph, trisomy 8, isochromosome 17q, and trisomy 19. The WHO includes provisional response-to-tyrosine kinase inhibitor criteria for accelerated phase disease.</div><div class="graphic_footnotes">WHO: World Health Organization; PB: peripheral blood; BM: bone marrow; pro: promyelocytes; baso: basophils; WBC: white blood cell count; RBC: red blood cells.<br/>* Kantarjian, HM, et al. Cancer 1988; 61:1441.<br/>¶ Sokal, JE, et al. Semin Hematol 1988; 25:49.<br/>Δ Arber, DA, et al. Blood 2016; 127:2391.</div><div class="graphic_reference">For each of the three sets of criteria, the accelerated phase of chronic myelogenous leukemia is diagnosed if one or more of the listed features is present. Adapted from O'Dwyer, ME, et al. Blood 2002; 100:1628.</div><div id="graphicVersion">Graphic 60902 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
